STOCK TITAN

Zai Lab Executive's $7.6M Combined Stock Sales Raise Investor Attention

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Zai Lab Director and Officer Ying Du filed Form 144 indicating a proposed sale of 23,669 American Depositary Shares with an aggregate market value of $855,196.47 through Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on June 25, 2025, as part of compensation.

Notable recent trading activity by Du includes:

  • Multiple large sales in May 2025 totaling 196,389 shares with combined proceeds of $5.68 million
  • Two smaller sales in April 2025 totaling 8,753 shares for $305,978

The filing indicates the sale is partially intended to cover tax obligations from vested equity awards. Du has certified no knowledge of undisclosed material adverse information regarding Zai Lab's operations. The company has 486.85 million shares outstanding, and the proposed sale represents approximately 0.005% of total shares.

Positive

  • None.

Negative

  • Director and Officer Ying Du has sold 228,811 shares worth approximately $6.85M over the past 3 months, including a recent planned sale of 23,669 shares ($855K), indicating significant insider selling pressure
  • The pattern of large sequential sales (three 50,000 share blocks in May 2025) suggests systematic reduction of insider holdings

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many ZLAB shares is insider Ying Du planning to sell according to the Form 144 filed on June 28, 2025?

According to the Form 144 filing, Ying Du plans to sell 23,669 American Depositary Shares of Zai Lab Limited (ZLAB) with an aggregate market value of $855,196.47. The approximate date of sale is indicated as June 26, 2025, and the shares will be sold through Fidelity Brokerage Services LLC on NASDAQ.

How many ZLAB shares has Ying Du sold in the past 3 months before this Form 144 filing?

In the 3 months prior to this filing, Ying Du sold a total of 205,142 American Depositary Shares of ZLAB in multiple transactions: April 2, 2025: 5,808 shares ($208,473.51), April 4, 2025: 2,945 shares ($97,504.53), May 9-14, 2025: 196,389 shares across four transactions totaling approximately $5.68 million.

What is the reason for Ying Du's ZLAB share sale in June 2025?

According to the Form 144's remarks section, the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution. The shares being sold were acquired through Restricted Stock Vesting on June 25, 2025, as part of compensation.

What positions does Ying Du hold at ZLAB?

According to the Form 144 filing, Ying Du holds dual positions at Zai Lab Limited (ZLAB), serving as both an Officer and Director of the company.

What is the total number of ZLAB shares outstanding as of June 2025?

According to the Form 144 filing, Zai Lab Limited (ZLAB) has 486,853,250 shares or units outstanding at the time of the filing in June 2025.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.07B
106.96M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI